Clinical Trials

Clinical trials are research studies designed to evaluate a new drug or combination of drugs or a new use of a marketed drug. Plexxikon and its partners are currently conducting clinical trials in a number of disease indications and combination trials with other agents.

Additional information about our clinical trials is available at www.clinicaltrials.gov, which gives an overview of the clinical trials process and lists a central database of all clinical trials in the U.S. For more information, please contact Plexxikon at 510-647-4000, or at plexxikondrug@plexxikon.com.

Compound Relevant Target Targeted Cancer Indication Link to clinicaltrials.gov

pexidartinib

CSF-1R

TGCT/PVNS/GCT-TS1 NCT02371369

pexidartinib + eribulin

CSF-1R, KIT Metastatic Breast Cancer NCT01596751

pexidartinib + paclitaxel

CSF-1R, KIT Advanced Ovarian Cancer NCT01525602

pexidartinib + pembrolizumab

CSF-1R

Solid Tumors

NCT02452424

pexidartinib + durvalumab

CSF-1R Colorectal, Pancreas Cancer NCT02777710

pexidartinib (China, EU)

KIT KIT-Mutant Melanoma NCT02975700
NCT02071940

pexidartinib

CSF-1R Pediatric Neurofibromatosis Type 1 NCT02390752

pexidartinib + sirolimus

CSF-1R Malignant Peripheral Nerve Sheath Tumors NCT02584647

pexidartinib + RT +ADT

CSF-1R Prostate Cancer NCT02472275

PLX7486

TRK, CSF-1R

Solid Tumors NCT01804530

PLX9486

KIT-Mutant

Gastrointestinal Stromal Tumor, KIT-Mutant Tumors NCT02401815

PLX8394

BRAF

BRAF-Mutant Tumors NCT02428712

PLX51107

BET

Solid Tumors, Hematologic Malignancies NCT02683395

PLX73086

CSF-1R

Solid Tumors NCT02673736

For more information about clinical trials of vemurafenib:

In the U.S.:
Phone: 1-888-662-6728, Monday-Friday, 9am - 6pm (ET)
Email: genentechclinicaltrials@druginfo.com
Web: www.clinicaltrials.gov

Outside the U.S.:
Web: www.roche-trials.com